Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 Mar 9;170(2):293–302. doi: 10.1007/s10549-018-4745-7

Table 1.

Clinical and pathologic characteristics of the patient population overall and by PD-L1 (clone 28-8 and 22C3) expression in tumor

Clone 28-8 in tumor
Clone 22C3 in tumor
Overall ≥1% <1% p-value ≥1% <1% p-value
(n=191) (n=49) (n=142) (n=22) (n=169)
Age, years, median (range) 52 (25-86) 52 (31-74) 53 (25-86) 0.35 53 (33-72) 52 (25-86) 0.70
Nottingham grade, n (%) 0.01 0.32
 1-2 55 (28.8) 7 (14.3) 48 (33.8) 4 (18.2) 51 (30.2)
 3 136 (71.2) 42 (85.7) 94 (66.2) 18 (81.8) 118 (69.8)
Tumor Size, mm, median (range) 21 (1-80) 25 (8-80) 20 (1-70) 0.01 22 (8-45) 20 (1-80) 0.20
T-stage, n (%) 0.05 0.07
 0 1 (0.5) 0 (0) 1 (0.7) 0 (0) 1 (0.6)
 1 94 (49.2) 17 (34.7) 77 (54.2) 6 (27.3) 88 (52.1)
 2 88 (46.1) 28 (57.1) 60 (42.3) 14 (63.6) 74 (43.8)
 3 6 (3.1) 3 (6.1) 3 (2.1) 1 (4.5) 5 (3.0)
 4 2 (1.1) 1 (2.0) 1 (0.7) 1 (4.5) 1 (0.6)
N-stage, n (%) 0.92 0.39
 0 78 (40.8) 21 (42.9) 57 (40.1) 8 (36.4) 70 (41.4)
 1 72 (37.7) 18 (36.7) 54 (38.0) 10 (45.5) 62 (36.7)
 2 25 (13.1) 7 (14.3) 18 (12.7) 4 (18.2) 21 (12.4)
 3 16 (8.4) 3 (2.0) 13 (9.2) 0 (0) 16 (9.5)
Hormonal receptor, n (%) 0.03 1.00
 Positive 75 (39.3) 26 (53.1) 49 (34.5) 9 (40.9) 66 (39.1)
 Negative 115 (60.2) 23 (46.9) 92 (64.8) 13 (59.1) 102 (60.4)
Hormonal Therapy, n(%) 0.06 1.00
 No 72(37.7) 24(49.0) 48(33.8) 8(36.4) 64(37.9)
 Yes 109(57.1) 22(44.9) 87(61.3) 12(54.5) 97(57.4)
Radiation Therapy, n(%) 0.85 0.294
 No 47(24.6) 13(26.5) 34(23.9) 3(13.6) 44(26.0)
 Yes 141(73.8) 35(71.4) 105(73.9) 19(86.4) 122(72.2)
Trastuzumab, n(%) 0.066 0.010
 No 76(39.8) 14(28.6) 62(43.7) 3(13.6) 73(43.2)
 Yes 115(60.2) 35(71.4) 80(56.3) 19(86.4) 96(56.8)
TIL-Str, %, median (range) 15 (0-85) 30 (0-85) 15 (0-65) <0.001 40 (7.5-85) 15 (0-65) <0.001